Fludarabinphosphat-GRY® 25 mg/ml Konzentrat zur Herstellung einer Injektionslösung oder Infusionslösung

DRUG2 trials

Sponsors

Celgene Corp., Charite Universitaetsmedizin Berlin KöR

Conditions

ANCA-IgG-positive ANCA associated vasculitisNewly Diagnosed Multiple Myeloma with Suboptimal Response After Autologous Stem Cell Transplantation

Phase 1

Anti-CD 19 CAR-T cell therapy in patients with ANCA Vasculitis: A two-stage interventional, prospective, open-label, phase I/II trial in patients with active, treatment refractory, ANCA-IgG-positive vasculitis

Not yet recruitingCTIS2024-517303-36-00

Charite Universitaetsmedizin Berlin KöRANCA-IgG-positive ANCA associated vasculitis

Target: 8Updated: 2024-12-09

Phase 3

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Active, not recruitingCTIS2022-501346-30-00

Celgene Corp.Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autologous Stem Cell Transplantation

Start: 2023-09-25Target: 332Updated: 2025-12-09